Innovations in anthracycline therapy: Overview

Community Oncology

Volumn 2, Issue SUPPL. 1, 2005, Pages 3-7

  Thigpen, J Tate ^a,b  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; LIPOSOME; METHOTREXATE; PACLITAXEL; PLATINUM DERIVATIVE; POLYETHYLENE; RAZOXANE; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ALOPECIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; EXTRAVASATION; HEART ARRHYTHMIA; HEART MUSCLE INJURY; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; META ANALYSIS; MUCOSA INFLAMMATION; NAUSEA; OVARY CANCER; QUALITY OF LIFE; REVIEW; SOLID TUMOR; SYSTEMATIC REVIEW;

EID: 13244281955     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Winer EP, Morrow M, Osborne CK, et al. Malignant tumors of the breast. In: DeVita VT Jr, Hellman S, Rosenberg RA (eds): Cancer: Principles & Practice of Oncology. 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:1651-1717.
2. Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998;351:1451-1467.
3. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin and cisplatin in women with ovarian cancer: the ICON3 randomized trial. Lancet 2002;360:505-515.
4. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: meta-analysis. The Ovarian Cancer Meta-Analysis Project. J Clin Oncol 1991;9:1668-1674.
5. Fanning J, Bennett TZ, Higers RD. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol 1992;80:954-960.
6. West RJ, Zweig SF. Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide, and doxorabicin versus cisplatin and cyclophosphamide. Eur J Gynaecol Oncol 1997;18:343-348.
7. A'Hern P, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995;13:726-732.
8. Balmer C, Valley AW. Basic principles of cancer treatment and cancer chemotherapy. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds): Pharmacotherapy: A Pathophysiologic Approach. 3rd ed. Stamford, Conn: Appleton & Lange; 1997:2403-2465.
9. Waterhouse DN, Tardi PG, Mayer LD, Bally MB, A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles. Drug Saf 2001;24:903-920.
10. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000;22:263-302.
11. Maluf FC, Spriggs D. Anthracyclines in the treatment of gynecologic malignancies. Gynecol Oncol 2002;85:18-31.
12. Hortobagyi GN. Anthracyclines in the treatment of cancer: an overview. Drugs 1997;54(suppl 4):1-7.
13. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-717.
14. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin. Cancer 2003;97:2869-2879.
15. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996;125:47-58.
16. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
17. Birtle AJ. Anthracyclines and cardiotoxicity. Clin Oncol (R Coll Radiol) 2000;12:146-152.
18. Seymour L, Bramwell V, Moran LA. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 1999;3:145-159.
19. Kaklamani VG, Gradishar WJ. Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer? Clin Breast Cancer 2003;4(suppl 1): S26-S33.
20. Findlay BP, Walker-Dilks C. Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 1998;2:140-146.
21. du Bois A, Combe M, Rochon J, et al. Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stages IIb-IV: an AGO-GINECO Intergroup phase III trial. In: Program/Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, La, Abstract 5007.
22. Kristensen GB, Vergote I, Eisenhauer E, et al. First line treatment of ovarian/tubal/ peritoneal cancer GICO stage IIb-IV with paclitaxel/carboplatin with or without epirubicin (TEC vs TC): a Gynecologic Cancer Intergroup study of the NSGO, EORTC GCG, and NCIC CTG. Results on progression-free survival. In: Program/Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, La. Abstract 5003.
23. Tardi PG, Boman NL.Cullis PR. Liposomal doxorubicin. J Drug Target 1996;4:129-140.
24. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubiein: rationale for use in solid tumours. Drugs 1997;54(suppl 4):15-21.
25. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54:987-992.
26. O'Brien MER, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-449.
27. 2. Ann Oncol 2000;11:1029-1033.
28. Muggia F, Kim E, Gaiotti D, et al. Safety and response of prolonged Doxil therapy in recurrent gynecologic cancers. In: Program/ Proceedings of the 40th Annual Meeting of the American Society of Clinical Oncology; June 5-8, 2004; New Orleans, La. Abstract 5055.
29. Uyar D, Kulp B, Peterson G, et al. Cardiac safety profile of prolonged (≥ 6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies. Gynecol Oncol 2004;94:147-151.
30. Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004;95:1-8.